Navigation Links
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Date:7/10/2008

Provides Update on Carfilzomib Development Program in Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc. today announced that patient dosing has commenced in a Phase 1b clinical trial to evaluate the safety and efficacy of Proteolix's lead anti-cancer agent, carfilzomib (PR-171), in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Carfilzomib selectively blocks proteasome activity, causing apoptosis in cancer cells. In single agent Phase 1 studies carfilzomib has demonstrated encouraging anti-tumor activity and has been generally well tolerated.

The Phase 1b clinical trial is designed to evaluate safety and to establish a maximum-tolerated dose of carfilzomib in combination with lenalidomide and dexamethasone on a twenty-eight day treatment cycle. Lenalidomide in combination with dexamethasone is indicated for use in patients with multiple myeloma who have had at least one prior therapy. Patients will be divided into four cohorts and will receive escalating doses of carfilzomib and lenalidomide, combined with a set dose of dexamethasone. A secondary endpoint for the trial is overall response rate at four months.

"Carfilzomib has been generally well-tolerated in patients and we believe that the product's selectivity and potency provide a solid rationale for use in combination with existing treatment protocols," said Lori Kunkel, M.D., Proteolix's Chief Medical Officer. "Initiating our first combination trial of carfilzomib complements our multi-pronged strategy to thoroughly explore carfilzomib's potential in the treatment of patients with multiple myeloma for whom treatment options may be limited."

Carfilzomib Clinical Program in Multiple Myeloma

In addition to the Phase 1b clinical trial announced today, Proteolix is currently evaluating carfilzomib as a single agent for the treatment of multiple myeloma in two Phase 2 clinical trials.

A Pha
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., FREMONT,Calif.,Nov.24/PRNewswire-FirstCall/--V...CompanyfileditsPlanofReorganizationandDisclosureSt...nkruptcyCourtfortheDistrictofDelaware.Ahearingtoco...cheduledforDecember8,2009,withthehearingontheconfi...hePlancallsfortheCompanytopayallclaimsinfull.ThePl...
(Date:11/24/2009)..., SANDIEGO,Nov.24/PRNewswire/--Accumetrics,Inc.,...#174;System,thefirstrapidandeasy-to-usediagnostics...ntiplateletagents(e.g.Plavix®andaspirin),anno...metrics,andGregoryJ.Tibbitts,ChiefFinancialOfficer...the21stAnnualPiperJaffrayHealthCareConferencebeing...
(Date:11/24/2009)..., SANDIEGO,Nov.24/PRNewswire/--AmbitBiosciencesC...sentationsevaluatingAC220,anovelsecondgenerationFL...ogyAnnualMeeting(ASH)tobeheldinNewOrleans,LA,Decem...fromanongoingclinicalPhaseImonotherapysafetystudyi...non-clinicaldatawillbepresentedevaluatingtheeffect...
Breaking Medicine Technology:Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 3Private Care Association of Floridas Elects Jim Mark as Vice President 58579 1Private Care Association of Floridas Elects Jim Mark as Vice President 58579 2Video 3A Worksite Wellness Programs Lower Healthcare Costs Make Employees Healthier 58577 1Video 3A Worksite Wellness Programs Lower Healthcare Costs Make Employees Healthier 58577 2Video 3A Worksite Wellness Programs Lower Healthcare Costs Make Employees Healthier 58577 3Video 3A Worksite Wellness Programs Lower Healthcare Costs Make Employees Healthier 58577 4Heartland Information Services Appoints New Chief Executive Officer 58575 1Heartland Information Services Appoints New Chief Executive Officer 58575 2
(Date:11/24/2009)...YORK,Nov.24/PRNewswire/-- Asyear-endapproaches,ma...taxesthisyearandnext.Tohelpyoutakeadvantageofthese...iorTaxAnalystatThomsonReuters,highlightsthefollowi..., Healthflexiblespendingaccounts(HealthFSAs) ...tytosavetaxesbyplacingfundsintheiremployer,shealth...
(Date:11/24/2009)...ESUCCESS,N.Y.,Nov.24/PRNewswire-USNewswire/--IPROh...ternationalqualitymanagementstandardfocusedonfulfi...ctionandcontinuallyimprovingbusinessperformance.Ce...cationServicesmeansIPRO,sQualityManagementSystem(Q...ationsatitsofficesinLakeSuccessandAlbany,NewYorkas...
(Date:11/24/2009)... Physician recruiting firm LocumTene...staffing, is pleased to announce its agreement wit...ide physicians for locum tenens assignments. , ...ber 24, 2009 -- Physician recruiting firm Locum...cian staffing, is pleased to announce its agreemen...
(Date:11/24/2009)... The molecular cause of inflammatory...ll be presented at the upcoming 2009 Advances in I...; Colitis Foundation’s Clinical & Resear... that may identify a causative mutation for Crohn&...rk, NY (Vocus) November 24, 2009 -- The molecular ...
(Date:11/24/2009)...RISBURG,Pa.,Nov.24/PRNewswire-USNewswire/--Governo...niansat-riskfortheH1N1fluwerevaccinatedduringthewe...lthandlocalhealthdepartments. ,, "Withthefedera...ectionsregardingtheavailabilityofH1N1vaccine,distr...erall,wearepleasedwiththeH1N1vaccinedistributionpr...
Breaking Medicine News(10 mins):Health News:The Right Tax Moves for Employees to Make Before Year-End 2Health News:The Right Tax Moves for Employees to Make Before Year-End 3Health News:IPRO Earns Third Consecutive Quality Management Certification 2Health News:VHA Names LocumTenens.com as Preferred Physician Staffing Vendor 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 2Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 3Health News:Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research 4Health News:Governor Rendell Announces 100,000 At-Risk Pennsylvanians Vaccinated at H1N1 Public Health Clinics; Addresses Future Vaccine Distribution Plans 2
..., Del., Oct. 4 More than 125 leaders,from through...ined together,to support a multi-year, statewide c...the Nation. The campaign, launched by Nemours Heal...,parents, and other leaders to improve the motivat...
...GTON, Oct. 4 Asbestos in the U.S. may,be breathin...an Asbestos in,America Act. Passage in the House i...atty Murray (D-WA) for the past six years, this le...o), and other,asbestos-related diseases, and launc...
...TH, Minn. and REDWOOD CITY, Calif., Oct. 4 /PRNews...oxHollow Technologies, Inc. (Nasdaq: FOXH ),annou...iously announced,merger under which ev3 has now ac... combined to create an organization that,possesses...
...ANCISCO, Oct. 4 Wells Fargo (NYSE: WFC ),today i...ses and,individuals to administer health care bene... Benefit Services to reduce,paperwork and increase...ernet portal, the Commercial Electronic,Office(R) ...
...ce Creates 3rd Largest Health Network, BELLEVUE, ...oup (RHG), owner of one of the Internet,s fastest ...aq: DSCM ), a leading online provider of,health, ...he Revolution Health Network and manage advertisin...
...earchers at the Agency for Science, Technology and...ll Biology (IMCB) have discovered new molecular me...g of how the normally benign Dr. Jekyll-like fungu...life-threatening infections in the mouth, blood an...
Other Medicine News:Health News:Governor Ruth Ann Minner, U.S. Senator Tom Carper, U.S. Representative Mike Castle and Lt. Governor John Carney Join 125 Delaware Community Leaders Endorsing the Campaign to Make Delaware's Kids the Healthiest in the Nation 2Health News:Governor Ruth Ann Minner, U.S. Senator Tom Carper, U.S. Representative Mike Castle and Lt. Governor John Carney Join 125 Delaware Community Leaders Endorsing the Campaign to Make Delaware's Kids the Healthiest in the Nation 3Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 2Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 3Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 4Health News:ev3 and FoxHollow Technologies Announce Completion of Merger 2Health News:ev3 and FoxHollow Technologies Announce Completion of Merger 3Health News:ev3 and FoxHollow Technologies Announce Completion of Merger 4Health News:ev3 and FoxHollow Technologies Announce Completion of Merger 5Health News:Wells Fargo Offers Online Benefit Administration for Business and Individual Healthcare Consumers 2Health News:Wells Fargo Offers Online Benefit Administration for Business and Individual Healthcare Consumers 3Health News:drugstore.com and Revolution Health Group Announce Breakthrough Deal 2Health News:drugstore.com and Revolution Health Group Announce Breakthrough Deal 3Health News:How Candida albicans transforms from its normally benign form into life-threatening form 2
...accurate bedside test for the easy to use Cardiac ...nt of patients with suspected Congestive Heart Fai...acy profit from a test combining speed (measuring...emergency departments Point of Care Testing on ave...
SpeediCath™ Female
...rgery. ,By using Perfluoron, a liquid tool compo...y expand your surgical capabilities. Perfluoron is...d by proliferative vitreoretinopathy, giant retina...ercent pure, Perfluoron is the purest perfluorocar...
Epocrates Dx
Medicine Products: